Erratum to: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion
نویسندگان
چکیده
1 SOD Cure Palliative e Terapia del Dolore, Ospedale Universitario Careggi, Florence, Italy 2 SC Anestesia, Rianimazione e Terapia Antalgica, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy 3 Fondazione ANT Italia Onlus, Andria, Italy 4 SC Cure Palliative, Ospedale di Biella, Ponderano, BI, Italy 5 UO Terapia del Dolore, ARNAS Civico di Palermo, Palermo, Italy 6 Hospice e Cure Palliative, ASP 1di Agrigento, Agrigento, Italy 7 UOC Terapia del Dolore e Cure Palliative, Azienda ospedaliera di Cosenza, Cosenza, Italy 8 Past President Feder Dolore-SICD, Cosenza, Italy 9 Struttura di Medicina del Dolore, Ospedale Universitario ‘‘Ospedali Riuniti’’, Foggia, Italy 10 UOS Cure Palliative e Terapia Antalgica, Azienda ULSS N. 10 ‘‘Veneto Orientale’’, San Donà di Piave, VE, Italy 11 USC Cure Palliative Terapia del Dolore, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy 12 UOD Terapia del Dolore e Cure Palliative, ACO San Filippo Neri, ASLRME, Rome, Italy Table 1 Characteristics of opioids used for BTP (times in minutes)
منابع مشابه
Reply—Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion
We would like to thank Raffaele Giusti and colleagues [1] for their comments on our paper [2]. Consistent with the motto ‘‘Actions speak louder than words’’, we have gathered a group of opinion leaders in palliative care and pain treatment who, for several years, have been committed to treat breakthrough cancer pain (BTcP). Our experience, gained by close contact with cancer pain sufferers, has...
متن کاملDiagnostic and therapeutic challenges for dermatologists: What shall we do when we don’t know what to do?
What shall we do when we have done everything we could for the diagnosis and treatment of a patient, but were not successful? What shall we do when there is no definite treatment for a patient? What shall we do when we have no diagnosis or treatment for a patient? Some useful suggestions are presented here to get rid of these situations.
متن کاملMeaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients.
OBJECTIVES To assess the level of pain intensity at which patients feel the impetus to ask for a breakthrough cancer pain (BTcP) medication, and level of pain intensity at which patients consider they have achieved acceptable pain control after receiving a BTcP medication. METHODS A consecutive sample of patients who were receiving oral morphine equivalents equal to or more than 60 mg daily, ...
متن کاملFentanyl for the treatment of tumor-related breakthrough pain.
BACKGROUND Breakthrough cancer pain (BTCP) is common among cancer patients and markedly lowers their quality of life. The treatment for BTCP episodes that is recommended in current guidelines involves extended-release formulations in combination with rapid-onset and short-acting opioids. In the past few years, several new preparations of fentanyl, an opioid with a very rapid onset, have been ap...
متن کاملA Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting
PURPOSE We evaluated the prevalence and characteristics of breakthrough cancer pain (BTcP) in Korean patients admitted with cancer pain. MATERIALS AND METHODS In-hospital patients with cancer pain completed a questionnaire concerning severity of background cancer pain (BCP), prevalence and treatment for BTcP, sleep disorders, and satisfaction with cancer pain treatment. Medical records showin...
متن کامل